Moderna and Merck report late-stage win for personalized melanoma vaccine with Keytruda

Moderna and Merck & Co. said their personalized cancer vaccine program produced positive late-stage results when paired with Keytruda in melanoma, a combination that targets tumors using a patient-specific approach while relying on an immune checkpoint drug to amplify the response.

In an Aug. 19, 2026 update reported by Yahoo Finance, Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) said their Phase 3 study met its goals for intismeran, Moderna’s personalized melanoma vaccine, in combination with Keytruda. The trial enrolled 1,137 patients, according to the report.

Intismeran is designed to tailor the immune stimulus to an individual’s melanoma, an approach intended to help the body recognize tumor-specific targets more effectively than one-size-fits-all therapies. Keytruda, Merck’s anti-PD-1 therapy, is widely used across several cancers and works by releasing the brakes on T-cells.

The companies did not provide, in the published item, the specific clinical endpoints that were achieved, the magnitude of benefit, or the statistical thresholds used to define success. The report also did not break out efficacy results by patient subgroup or summarize detailed safety findings.

Moderna has built its broader oncology strategy around personalized messenger RNA (mRNA) platforms, where genetic instructions are delivered into the body to prompt an immune response against selected targets. For partners, the strategy can lower some biological uncertainty by combining individualized immune activation with established oncology backbones such as PD-1 blockade.

For Merck, the reported result sits within a competitive push in melanoma and other solid tumors, where the field has shifted toward combinations that combine immune stimulation with checkpoint inhibition. Keytruda’s role in the program underscores that Merck is looking to extend and defend its immunotherapy franchise by pairing it with new modalities rather than relying on monotherapy.

Still, important details were not included in the Yahoo Finance post. The companies did not specify whether the trial met primary endpoints, key secondary endpoints, or both, nor did it disclose hazard ratios, survival curves, response rates, or adverse-event rates in the text reviewed here.

What to watch next is how Moderna and Merck describe the trial in full, including the primary efficacy measures, the durability of responses, and the tolerability profile of the combination. Additional disclosures around regulatory plans and timelines would also clarify whether the companies anticipate filing submissions based on the Phase 3 outcome.